Drugs News and Research

RSS

Scientific workshop to focus on advanced analytical techniques

Almac, in association with the Royal Society of Chemistry, hosted a scientific workshop focusing on advanced analytical techniques used to optimise, monitor and control solid state properties during the development of new medicines.

20 Nov 2010

CMS notifies Health Net about intermediate sanction on compliance with Part D requirements

Health Net, Inc. announced today that the Centers for Medicare & Medicaid Services (CMS) notified the company of its intent to impose intermediate sanctions suspending the marketing and enrollment of new members of all Health Net Medicare Advantage Prescription Drug (MAPD) and stand-alone Prescription Drug Plan (Part D) contracts, effective November 20, 2010.

20 Nov 2010

Xanodyne to withdraw propoxyphene-containing products from the U.S. market

Xanodyne Pharmaceuticals, Inc. announced today that the company will voluntarily withdraw its Darvon, Darvon-N and Darvocet-N products from the U.S. market in consultation with the U.S. Food and Drug Administration (FDA).

20 Nov 2010

Children's Surgical Centre offers no-cost surgery for children with frontoethmoidal meningoencephalocele

Frontoethmoidal meningoencephalocele is a type of facial malformation that is rarely seen in developed countries, but is quite common in many Southeast Asian countries, occurring in 1 of every 5,000 live births.

20 Nov 2010

National Marrow Donor Program adopts IBM's WebSphere Lombardi Business Process Management software

IBM announced today that the National Marrow Donor Program® (NMDP) has adopted IBM's WebSphere Lombardi Business Process Management (BPM) software to help automate its donor and patient management process. Both processes are critical to facilitate the matching of donors to patients needing cellular transplants.

20 Nov 2010

Medco shares 10-year strategic financial plan

Medco Health Solutions, Inc. today presented the results of a recently completed strategic financial plan that forecasts a decade of substantial growth through 2020.

20 Nov 2010

Survey examines Canadians' overall view of health care system

Today, the Health Council of Canada released survey results from the 2010 Commonwealth Fund International Health Policy Survey. The bulletin called, How Do Canadians Rate the Health Care System? examines Canadians' insights into the performance of the health care system.

20 Nov 2010

New I-SPY 2 study to evaluate effectiveness of medical treatment for breast cancer

A clinical trial that aims to speed up the study of new treatments for certain subtypes of breast cancer now has a designated study site at the Diane O'Connor Thompson Breast Center at the University of Colorado Hospital.

20 Nov 2010

USC Norris designated Phase I Clinical Trial Center of Excellence

The USC Norris Comprehensive Cancer Center (USC Norris) has been designated a Phase I Clinical Trial Center of Excellence by global pharmaceutical company Bristol-Myers Squibb Company. The collaboration will bring a number of new phase I clinical trials to USC Norris, and will enable the cancer center's clinical and basic scientists to provide guidance in early phase drug development and trial design.

20 Nov 2010

One-third of malaria-endemic countries are complying with WHO malaria drug efficacy monitoring standards, report says

Thirty-four percent of malaria-endemic countries are complying with WHO guidelines to monitor artemisinin resistance within their borders, the agency said in a report on Thursday, CBS News reports (11/18). Reuters reports that artemisinin "is the best drug available against malaria, especially when used in artemisinin combination therapy (ACT), which combines it with other drugs that finish off the [malaria] parasite" (Nebehay, 11/18).

20 Nov 2010

Xanodyne Pharmaceuticals decides to voluntarily remove propoxyphene from the U.S. market

Xanodyne Pharmaceuticals Inc. which makes Darvon and Darvocet, the brand version of the prescription pain medication propoxyphene, has agreed to withdraw the medication from the U.S. market at the request of the U.S. Food and Drug Administration. The FDA has also informed the generic manufacturers of propoxyphene-containing products of Xanodyne's decision and requested that they voluntarily remove their products as well.

20 Nov 2010

NexACT technology improves oral delivery of five small molecule drugs

Apricus Biosciences, Inc., today announced data from animal studies showing that the NexACT technology significantly improved the oral delivery of five small molecule drugs tested, with the best improvements up to 20-fold, in terms of improvement in absorption.

20 Nov 2010

Acceleron presents ACE-041 interim results for advanced cancer at EORTC-NCI-AACR Symposium

Acceleron Pharma, Inc., a biopharmaceutical company developing novel protein therapeutics that regulate the growth and development of tissues and cells, including muscle, bone, red blood cells, and vasculature, today announced the presentation of interim results from the first-in-human clinical study of ACE-041 in patients with advanced cancer at the 22nd EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Berlin, Germany.

20 Nov 2010

Reprogrammed amniotic fluid cells can generate iPS cells

Reprogrammed amniotic fluid cells can generate all types of body cells. High hopes rest on stem cells: one day, they may be used to treat many diseases. To date, embryos are the main source of these cells, but this raises ethical problems. Scientists at the Max Planck Institute for Molecular Genetics in Berlin have now managed to convert amniotic fluid cells into pluripotent stem cells.

20 Nov 2010

FDA-approved anti-parasite drug blocks Wnt signaling pathway in colon cancer

An old pinworm medicine is a new lead in the search for compounds that block a signaling pathway implicated in colon cancer. The findings, reported by Vanderbilt University Medical Center researchers in the November issue of Nature Chemical Biology, suggest a fresh approach for developing therapeutics that target the pathway.

20 Nov 2010

States focus on Medicaid budget challenges

Nearly missed in the noise from newly elected politicians vowing to upend the Obama administrations health care reform law was a federal decision allowing California to start implementing it and improve its fiscal situation in the process. On Election Day, California got word it would receive $10 billion in federal Medicaid money to extend coverage to some 500,000 people who are currently uninsured. ...

20 Nov 2010

Antares advances VIBEX QS platform for highly-viscous drug injection

Antares Pharma, Inc., a leader in self-injection drug delivery technology, today announced the latest advancement in its proprietary line of VIBEX auto-injectors.

20 Nov 2010

CMS grants Qutenza J-code to NeurogesX

NeurogesX, Inc. a biopharmaceutical company focused on developing and commercializing novel pain management therapies, today announced that the Centers for Medicare and Medicaid Services (CMS) has granted a unique, Level II Health Care Common Procedural Coding System (Level II HCPCS), commonly referred to as a J-code, for Qutenza (capsaicin) 8% patch.

19 Nov 2010

Xgeva receives FDA approval for prevention of SREs in patients with bone metastases

The U.S. Food and Drug Administration approved Xgeva (denosumab) on Thursday to help prevent skeletal-related events (SREs) in patients with cancer that has spread (metastasized) and damaged the bone. Skeletal-related events include bone fractures from cancer and bone pain requiring radiation.

19 Nov 2010

Stromedix obtains license from UCSF for integrin αvβ5 antibody

Stromedix, Inc., a biotechnology company focused on innovative therapies for fibrosis and organ failure, announced today that it has exclusively licensed the rights to a monoclonal antibody to integrin αvβ5 from the University of California. This compound is the second Stromedix pipeline asset to be sourced from the laboratory of Dean Sheppard, M.D., at University of California, San Francisco.

19 Nov 2010

Drugs News and Research

Scientific workshop to focus on advanced analytical techniques

CMS notifies Health Net about intermediate sanction on compliance with Part D requirements

Xanodyne to withdraw propoxyphene-containing products from the U.S. market

Children's Surgical Centre offers no-cost surgery for children with frontoethmoidal meningoencephalocele

National Marrow Donor Program adopts IBM's WebSphere Lombardi Business Process Management software

Medco shares 10-year strategic financial plan

Survey examines Canadians' overall view of health care system

New I-SPY 2 study to evaluate effectiveness of medical treatment for breast cancer

USC Norris designated Phase I Clinical Trial Center of Excellence

One-third of malaria-endemic countries are complying with WHO malaria drug efficacy monitoring standards, report says

Xanodyne Pharmaceuticals decides to voluntarily remove propoxyphene from the U.S. market

NexACT technology improves oral delivery of five small molecule drugs

Acceleron presents ACE-041 interim results for advanced cancer at EORTC-NCI-AACR Symposium

Reprogrammed amniotic fluid cells can generate iPS cells

FDA-approved anti-parasite drug blocks Wnt signaling pathway in colon cancer

States focus on Medicaid budget challenges

Antares advances VIBEX QS platform for highly-viscous drug injection

CMS grants Qutenza J-code to NeurogesX

Xgeva receives FDA approval for prevention of SREs in patients with bone metastases

Stromedix obtains license from UCSF for integrin αvβ5 antibody

Industry Focus eBook - Analytical Chemistry (2nd Edition) eBook

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News